MS Views and News Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter

MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click:

Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Friday, August 15, 2014

Cannabis-based multiple sclerosis drug approved in Wales but could be blocked in England (UK confusion?)

Sativex, a cannabis-derived drug for treating muscle spasms in multiple sclerosis, gets green light in Wales but could still be blocked in England
GW Pharmaceuticals (Stuttgart: A1T980 - news) ' cannabis-based multiple sclerosis drug Sativex will be made widely available in Wales, but could still be blocked in England.
The Welsh medicines board on Friday confirmed it had recommended Sativex to relieve muscle spasms in multiple sclerosis, as first reported in the Telegraph earlier this week.
Dr Sajida Javaid, a consultant in rehabilitation medicine at Neath Port Talbot Hospital hailed the Welsh recommendation as a "significant milestone for the treatment of spasticity".

Sativex was first launched in the UK in 2010, but patients have only been able to access the treatment on an ad hoc basis since, until now, authorities had issued no clear guidance on the use of the drug.

 Keep CURRENT and up to date, with MS News and Information
Sign-up for emails 



No comments: